An “All‐In‐One” Immunomodulator‐Engineered Clinical Translatable Immunotherapy of Advanced Hepatocellular Carcinoma
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202304476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Ting Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, Universi…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Doxorubicin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Hunan Science and Technology Innovation Leading Talent Project, Key R & D Program of Hunan province.
Abstract (Originalsprache)
Clinical treatment of advanced hepatocellular carcinoma (HCC) remains a significant challenge. Utilizing 1‐bromoacetyl‐3,3‐dinitroazetidine (RRx‐001) to downregulate the expression of innate immune checkpoint molecule, cluster of differentiation 47 (CD47), provides a powerful means for treating advanced HCC containing abundant immunosuppressive macrophages. Herein engineering of a previously optimized Doxorubicin (DOX)‐delivery nanoplatform based on sodium alginate is reported to further co‐deliver RRx‐001 (biotinylated aldehyde alginate–doxorubicin micelle prodrug nanoplatform, BEA‐D@R) for efficient immunotherapy of advanced HCC. This groundbreaking technique reveals the “all‐in‐one” immunotherapeutic functionalities of RRx‐001. Besides the previously demonstrated functions of downregulating CD47 expression and increasing reactive nitrogen species (RNS) generation, another key function of RRx‐001 for downregulating the expression of the adaptive immune checkpoint molecule programmed cell death 1 ligand 1 (PDL1) is first uncovered here. Combined with the reactive oxygen species (ROS) generation and an upregulated “eat me” signal level of DOX, BEA‐D@R collectively increases RNS generation, enhances T‐cell infiltration, and maximizes macrophage phagocytosis, leading to an average of 40% tumor elimination in a mice model bearing an initial tumor volume of ≈300 mm 3 that mimics advanced HCC. Overall, the “all‐in‐one” immunotherapeutic functionalities of a clinical translatable nanoplatform are uncovered for enhanced immunotherapy of advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, China.
- Affiliated Hospital of Hunan Academy of Chinese Medicine, Hunan Academy of Chinese Medicine, Changsha, 410013, China.
ORCID-Profile: Hua Wei
Förderung
- Hunan Science and Technology Innovation Leading Talent Project
- Key R & D Program of Hunan province
Zitieren
APA
Xie, T., Huang, C., Wang, Y., Zhang, H., Guo, P., Phann, T. T., Cheng, Y., Lei, L., Tao, Z., Gao, Q., Wei, H., & Yu, C. Y. (2024). An “All‐In‐One” Immunomodulator‐Engineered Clinical Translatable Immunotherapy of Advanced Hepatocellular Carcinoma. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202304476
Vancouver
Xie T, Huang C, Wang Y, Zhang H, Guo P, Phann TT, et al. An “All‐In‐One” Immunomodulator‐Engineered Clinical Translatable Immunotherapy of Advanced Hepatocellular Carcinoma. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202304476
BibTeX
@article{Xie2024,
author = {Xie, Ting and Huang, Cong and Wang, Yuqing and Zhang, Haitao and Guo, Pei and Phann, Thuy Thu and Cheng, Yao and Lei, Longtianyang and Tao, Zhenghao and Gao, Qing and Wei, Hua and Yu, Cui-Yun},
title = {An “All‐In‐One” Immunomodulator‐Engineered Clinical Translatable Immunotherapy of Advanced Hepatocellular Carcinoma},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202304476}
}
EUVIMED